Signal Genetics Company Profile (NASDAQ:SGNL)

About Signal Genetics

Signal Genetics logoSignal Genetics, Inc. is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company's diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test. The MyPRS test is a microarray-based gene expression profile (GEP), assay that measures the expression level of specific genes and groups of genes that are designed to predict an individual's long-term clinical outcome/prognosis, giving a basis for personalized treatment options. The Company's MyPRS test provides a whole-genomic expression profile of a patient's multiple myeloma (MM). The Company offers MyPRS test in its laboratory located in Little Rock, Arkansas. The Company is licensed to sell its test in all 50 states.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: SGNL
  • CUSIP:
Key Metrics:
  • Previous Close: $0.48
  • 50 Day Moving Average: $0.50
  • 200 Day Moving Average: $0.52
  • 52-Week Range: $0.40 - $1.14
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.66
  • P/E Growth: 0.00
  • Market Cap: $4.64M
  • Outstanding Shares: 10,790,000
  • Beta: 0.07
Additional Links:
Companies Related to Signal Genetics:

Analyst Ratings

Consensus Ratings for Signal Genetics (NASDAQ:SGNL) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.67 (731.44% upside)

Analysts' Ratings History for Signal Genetics (NASDAQ:SGNL)
DateFirmActionRatingPrice TargetDetails
8/21/2016Rodman & RenshawSet Price TargetBuy$4.00View Rating Details
1/26/2016AegisReiterated RatingBuyView Rating Details
1/8/2016HC WainwrightInitiated CoverageBuy$4.00View Rating Details
9/23/2015Chardan CapitalReiterated RatingBuy$2.75View Rating Details
(Data available from 10/21/2014 forward)


Earnings History for Signal Genetics (NASDAQ:SGNL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/16/2016Q116($0.28)($0.26)$645.00 million$808.00 millionViewN/AView Earnings Details
3/16/2016Q415($0.36)($0.28)ViewN/AView Earnings Details
8/12/2015Q215($0.39)($0.33)ViewN/AView Earnings Details
5/14/2015Q115($0.36)($0.45)$1.90 millionViewN/AView Earnings Details
3/30/2015($0.39)($1.72)ViewN/AView Earnings Details
11/14/2014($0.05)($0.43)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Signal Genetics (NASDAQ:SGNL)
Current Year EPS Consensus Estimate: $-0.940 EPS
Next Year EPS Consensus Estimate: $-0.670 EPS


Dividend History for Signal Genetics (NASDAQ:SGNL)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Signal Genetics (NASDAQ:SGNL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/20/2015Samuel D. RiccitelliCEOBuy14,000$0.79$11,060.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Signal Genetics (NASDAQ:SGNL)
News IconSignal Genetics, Inc. (SGNL) Updated Broker Price Targets (NASDAQ:SGNL) - October 12 at 9:35 AM logoSignal Genetics, Inc. (SGNL) - Financial and Strategic SWOT Analysis Review - New Market Research Report (NASDAQ:SGNL) - August 23 at 11:54 AM logoSignal Genetics, Inc. :SGNL-US: Earnings Analysis: Q2, 2016 By the Numbers : August 18, 2016 (NASDAQ:SGNL) - August 18 at 7:38 PM logoSIGNAL GENETICS, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:SGNL) - August 15 at 7:45 PM logoSIGNAL GENETICS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial (NASDAQ:SGNL) - June 23 at 4:06 PM logoSIGNAL GENETICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:SGNL) - June 16 at 5:28 PM
News IconAfter Last Week What Do Analysts Think Of Signal Genetics, Inc. (SGNL) - Share Trading News (NASDAQ:SGNL) - May 30 at 7:32 PM logoSignal Genetics Receives Extension to Comply with Nasdaq Continued Listing Requirement (NASDAQ:SGNL) - May 26 at 8:30 AM logoSignal Genetics to Present at the LD Micro Invitational (NASDAQ:SGNL) - May 25 at 8:30 AM logoSignal Genetics, Inc. :SGNL-US: Earnings Analysis: Q1, 2016 By the Numbers : May 23, 2016 (NASDAQ:SGNL) - May 23 at 12:14 PM logoSignal Genetics Highlights Recent Achievements and Reports First Quarter 2016 Financial Results (NASDAQ:SGNL) - May 16 at 8:30 AM logoSIGNAL GENETICS, INC. Files SEC form 10-K, Annual Report (NASDAQ:SGNL) - March 21 at 4:41 PM logoSignal Genetics, Inc. :SGNL-US: Earnings Analysis: 2015 By the Numbers (NASDAQ:SGNL) - March 21 at 11:57 AM logoSignal Genetics Highlights Recent Achievements and Reports Fourth Quarter and Full-Year 2015 Financial Results (NASDAQ:SGNL) - March 16 at 4:05 PM logoQ4 2015 Signal Genetics Inc Earnings Release - After Market Close (NASDAQ:SGNL) - March 16 at 7:07 AM logoSignal Genetics to Host 2015 Annual Corporate Update Call (NASDAQ:SGNL) - March 10 at 8:30 AM
News IconBrokerage Analyst Buys: Golar LNG Limited (NASDAQ:GLNG), Oncothyreon Inc. (NASDAQ:ONTY), Evoke Pharma, Inc ... - (NASDAQ:SGNL) - February 26 at 10:49 AM
News IconSignal Genetics Incorporated (NASDAQ:SGNL) Shorts Decreased by 4.99% After Short Covering - (NASDAQ:SGNL) - February 26 at 10:49 AM logoSignal Genetics, Inc. (SGNL) (NASDAQ:SGNL) - February 3 at 12:54 PM logoSignal Genetics, Inc. (NASDAQ: SGNL) Begins Patient Study for its MyPRS(R) Assay (NASDAQ:SGNL) - January 12 at 11:50 AM logoCoverage initiated on Signal Genetics by Rodman & Renshaw (NASDAQ:SGNL) - January 8 at 7:11 AM logoSignal Genetics and MD Anderson Cancer Center Enter Into Sponsored Research Agreement (NASDAQ:SGNL) - January 6 at 9:03 AM logoWhy Aegis Capital Loves Signal Genetics (NASDAQ:SGNL) - December 29 at 2:59 PM logoSIGNAL GENETICS, INC. Financials (NASDAQ:SGNL) - December 8 at 1:18 PM logoSIGNAL GENETICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Stand (NASDAQ:SGNL) - November 30 at 5:26 PM logoSignal Genetics to Present at the 8th Annual LD Micro Main Event (NASDAQ:SGNL) - November 24 at 8:43 AM logoSIGNAL GENETICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Fi (NASDAQ:SGNL) - November 13 at 4:02 PM logoSignal Genetics Highlights Recent Achievements and Reports Third Quarter 2015 Financial Results (NASDAQ:SGNL) - November 12 at 4:26 PM logoSignal Genetics' MyPRS(R) Highlighted in the Journal Leukemia (NASDAQ:SGNL) - November 5 at 8:50 AM logoSignal Genetics Expands Reimbursement of MyPRS(R) With Additional Preferred Provider Organization Agreements (NASDAQ:SGNL) - October 20 at 8:52 AM logoUpdated Presentation Time: Signal Genetics to Present at the 2015 Aegis Growth Conference (NASDAQ:SGNL) - October 2 at 9:00 AM logoSignal Genetics Granted First European Patent for MyPRS(R) (NASDAQ:SGNL) - September 24 at 8:58 AM logoSIGNAL GENETICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (NASDAQ:SGNL) - September 24 at 8:36 AM


Signal Genetics (NASDAQ:SGNL) Chart for Friday, October, 21, 2016

Last Updated on 10/21/2016 by Staff